[Results of treatment for advanced non-seminomatous germ cell tumors of the testis based on Indiana University classification].
From 1980 to 1990, we treated 45 patients with non-seminomatous germ cell tumors of greater than or equal to stage II according to the Japanese general rule for clinical and pathological studies on testicular tumors. The patients were divided into 2 groups based on the Indiana University Classification: 26 good risk patients (score < or = 6) and 19 poor risk patients (score > or = 7). The clinical results, the % dose intensity of Cisplatin and half-lives of tumor makers were analyzed in the two groups. The per cent dose intensity of Cisplatin of the induction chemotherapy was 61 +/- 24% in 1980-1985 and 87 +/- 18% in 1986-1990. The NED rate improved from 66.7% (10/15) to 81.8% (9/11) in the good risk patients and from 33.3% (3/9) to 50.0% (5/10) in the poor risk patients between the above two periods. When the % dose intensity of Cisplatin exceeded 80%, the NED rate increased from 66.7% (10/15) to 90.0% (9/10) in good risk patients and from 33.3% (2/6) to 45.5% (5/11) in poor risk patients. The NED rate was only 25.0% (4/16) in the poor risk patients whose residual tumors were not resected. The half-lives of AFP and beta-HCG from the latter part of the first course to the second course were 6.8 +/- 1.9 days and 4.4 +/- 1.4 days, respectively, in the patients with a good prognosis, while they were 6.5 +/- 1.5 days and 4.4 +/- 2.9 days, respectively, in with a poor prognosis.(ABSTRACT TRUNCATED AT 250 WORDS)
Okamura
K
K
Nagoya University Urologic Oncology Group.
Sahashi
M
M
Aota
Y
Y
Kobayashi
H
H
Suzuki
K
K
Tanaka
K
K
Shimoji
T
T
Murase
T
T
Yoshida
K
K
Ohshima
S
S
D000293:Adolescent; D000328:Adult; D014408:Biomarkers, Tumor / Q000378:metabolism; D002945:Cisplatin / Q000627:therapeutic use*; D018237:Germinoma / Q000145:classification / Q000188:drug therapy* / Q000401:mortality; D006207:Half-Life; D006801:Humans; D008297:Male; D011379:Prognosis; D015996:Survival Rate; D013736:Testicular Neoplasms / Q000145:classification / Q000188:drug therapy* / Q000401:mortality; D016896:Treatment Outcome
D014408:Biomarkers, Tumor; D002945:Cisplatin